A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy

• Status: Withdrawn
• Trial end date: 2019-08-22

Summary

This study will evaluate the safety and preliminary efficacy of venetoclax when combined with lenalidomide and dexamethasone for participants with newly diagnosed, active t(11;14) positive multiple myeloma (MM).

This study will consist of 2 parts: Part 1 Dose Escalation and Part 2 Dose Expansion.

• Phase: Phase 2

Details

• Lead Sponsor: AbbVie
• Collaborators: Celgene Corporation; Genentech, Inc.
• Treatments: BB 1101; Dexamethasone; Dexamethasone acetate; Lenalidomide; Thalidomide; Venetoclax